Reichert Technologies Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reichert Technologies Inc.
October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt. Regeneron’s $391 million notes sale propelled the debt category to claim almost half of the $826 million biopharma financing figure. Meantime device companies raised $206 million, mainly from Zeltiq’s $93 million IPO.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
- Research, Analytical Equipment & Supplies
- Diagnostic Equipment & Supplies
- Other Names / Subsidiaries
- Reichert Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.